Performance Status Modifies the Association Between Vitamin D Receptor Activator and Mortality or Fracture: A Prospective Cohort Study on the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry

ABSTRACT Immobilization osteoporosis is characterized by excess bone resorption. Vitamin D receptor activators (VDRA) might have adverse effects in immobilized patients. The objective of this study was to elucidate the impact of performance status (PS) on the associations between VDRA use and outcom...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of bone and mineral research 2022-08, Vol.37 (8), p.1489-1499
Hauptverfasser: Murashima, Miho, Hamano, Takayuki, Nishiyama, Takeshi, Tsuruya, Kazuhiko, Ogata, Satoshi, Kanda, Eiichiro, Abe, Masanori, Masakane, Ikuto, Nitta, Kosaku
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1499
container_issue 8
container_start_page 1489
container_title Journal of bone and mineral research
container_volume 37
creator Murashima, Miho
Hamano, Takayuki
Nishiyama, Takeshi
Tsuruya, Kazuhiko
Ogata, Satoshi
Kanda, Eiichiro
Abe, Masanori
Masakane, Ikuto
Nitta, Kosaku
description ABSTRACT Immobilization osteoporosis is characterized by excess bone resorption. Vitamin D receptor activators (VDRA) might have adverse effects in immobilized patients. The objective of this study was to elucidate the impact of performance status (PS) on the associations between VDRA use and outcomes among hemodialysis patients. This is a prospective cohort study. Adults on hemodialysis in the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry were included. Exposure of interest was the use of VDRA. Outcomes were all‐cause mortality and hip fracture. Associations between VDRA use and mortality or hip fractures were examined by Cox and Poisson regression analyses, respectively. Among 208,512 subjects, 128,535 were on VDRA. Poor PS was associated with higher calcium (Ca), lower parathyroid hormone, and higher alkaline phosphatase levels. The association between higher Ca levels and VDRA use was stronger among those with poor PS (p interaction 0.007). Adjusted hazard ratio (HR) (95% confidence interval [CI]) for mortality and incidence rate ratio (IRR) for hip fracture was 1.02 (95% CI, 0.99–1.05) and 0.93 (0.86–1.00) among users of VDRA, respectively. The VDRA use was associated with lower mortality and incidence of hip fractures among subjects with good PS but not among subjects with poor PS (p interaction 0.03 and 0.05). Effect modification by PS was observed for cardiovascular (CV) mortality but not for non‐CV mortality. In conclusion, VDRA use was associated with better outcomes only among those with good PS. These results suggest that bone and mineral disorders among hemodialysis patients should be treated differently, depending on their performance status. © 2022 American Society for Bone and Mineral Research (ASBMR).
doi_str_mv 10.1002/jbmr.4621
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2675606713</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2699902268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3961-d32278846de950efc6dc999d552d6957c2e49f32a1667498fc2a487eae5da9513</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhiMEEkvhwBtY4tIe0tpO4iTctruUdtWqVbtwjQZnwnqVxMF2qPKSPFMn3Z6QeprR6Jv5f80fRZ8FPxWcy7P9r86dpkqKN9FCZDKJU1WIt9GCF0Ua8zQR76MP3u855ypTahH9u0PXWNdBr5E9BAijZze2No1Bz8IO2dJ7qw0EY3t2juERsWc_TYDO9GzN7lHjEKxjSx3MX5g76Gu64AK0JkyMBhcOdBgdfmVLduesH3Bmka3sjjASHWvi-me1DQzQoycrJIq0T97Y2kA7eePZdocOhokdbx7W2xMS76FlawhA7W_jg5s-Ru8aaD1-eqlH0Y-Lb9vVZXx9-_1qtbyOdVIqEdeJlDl9RNVYZhwbrWpdlmWdZbJWZZZriWnZJBKEUnlaFo2WkBY5AmY1lJlIjqLjw93B2T8j-lB1xmtsW3JvR19JlWeKq1wkhH75D93b0ZHzmSJRLqUqiDo5UJo-5B021eBMB26qBK_mZKs52WpOltizA_toWpxeB6vN-c3988YTRYGn4A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2699902268</pqid></control><display><type>article</type><title>Performance Status Modifies the Association Between Vitamin D Receptor Activator and Mortality or Fracture: A Prospective Cohort Study on the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry</title><source>Wiley Online Library - AutoHoldings Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Murashima, Miho ; Hamano, Takayuki ; Nishiyama, Takeshi ; Tsuruya, Kazuhiko ; Ogata, Satoshi ; Kanda, Eiichiro ; Abe, Masanori ; Masakane, Ikuto ; Nitta, Kosaku</creator><creatorcontrib>Murashima, Miho ; Hamano, Takayuki ; Nishiyama, Takeshi ; Tsuruya, Kazuhiko ; Ogata, Satoshi ; Kanda, Eiichiro ; Abe, Masanori ; Masakane, Ikuto ; Nitta, Kosaku</creatorcontrib><description>ABSTRACT Immobilization osteoporosis is characterized by excess bone resorption. Vitamin D receptor activators (VDRA) might have adverse effects in immobilized patients. The objective of this study was to elucidate the impact of performance status (PS) on the associations between VDRA use and outcomes among hemodialysis patients. This is a prospective cohort study. Adults on hemodialysis in the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry were included. Exposure of interest was the use of VDRA. Outcomes were all‐cause mortality and hip fracture. Associations between VDRA use and mortality or hip fractures were examined by Cox and Poisson regression analyses, respectively. Among 208,512 subjects, 128,535 were on VDRA. Poor PS was associated with higher calcium (Ca), lower parathyroid hormone, and higher alkaline phosphatase levels. The association between higher Ca levels and VDRA use was stronger among those with poor PS (p interaction 0.007). Adjusted hazard ratio (HR) (95% confidence interval [CI]) for mortality and incidence rate ratio (IRR) for hip fracture was 1.02 (95% CI, 0.99–1.05) and 0.93 (0.86–1.00) among users of VDRA, respectively. The VDRA use was associated with lower mortality and incidence of hip fractures among subjects with good PS but not among subjects with poor PS (p interaction 0.03 and 0.05). Effect modification by PS was observed for cardiovascular (CV) mortality but not for non‐CV mortality. In conclusion, VDRA use was associated with better outcomes only among those with good PS. These results suggest that bone and mineral disorders among hemodialysis patients should be treated differently, depending on their performance status. © 2022 American Society for Bone and Mineral Research (ASBMR).</description><identifier>ISSN: 0884-0431</identifier><identifier>EISSN: 1523-4681</identifier><identifier>DOI: 10.1002/jbmr.4621</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>ALKALINE PHOSPHATASE ; Bone resorption ; CALCIUM ; Cardiovascular diseases ; Cohort analysis ; Fractures ; Hemodialysis ; Hip ; HIP FRACTURE ; Immobilization ; MORTALITY ; Osteoporosis ; Parathyroid hormone ; PERFORMANCE STATUS ; Vitamin D ; VITAMIN D RECEPTOR ACTIVATOR</subject><ispartof>Journal of bone and mineral research, 2022-08, Vol.37 (8), p.1489-1499</ispartof><rights>2022 American Society for Bone and Mineral Research (ASBMR).</rights><rights>2022 American Society for Bone and Mineral Research</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3961-d32278846de950efc6dc999d552d6957c2e49f32a1667498fc2a487eae5da9513</citedby><cites>FETCH-LOGICAL-c3961-d32278846de950efc6dc999d552d6957c2e49f32a1667498fc2a487eae5da9513</cites><orcidid>0000-0002-2100-9106 ; 0000-0002-2923-0438</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjbmr.4621$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjbmr.4621$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids></links><search><creatorcontrib>Murashima, Miho</creatorcontrib><creatorcontrib>Hamano, Takayuki</creatorcontrib><creatorcontrib>Nishiyama, Takeshi</creatorcontrib><creatorcontrib>Tsuruya, Kazuhiko</creatorcontrib><creatorcontrib>Ogata, Satoshi</creatorcontrib><creatorcontrib>Kanda, Eiichiro</creatorcontrib><creatorcontrib>Abe, Masanori</creatorcontrib><creatorcontrib>Masakane, Ikuto</creatorcontrib><creatorcontrib>Nitta, Kosaku</creatorcontrib><title>Performance Status Modifies the Association Between Vitamin D Receptor Activator and Mortality or Fracture: A Prospective Cohort Study on the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry</title><title>Journal of bone and mineral research</title><description>ABSTRACT Immobilization osteoporosis is characterized by excess bone resorption. Vitamin D receptor activators (VDRA) might have adverse effects in immobilized patients. The objective of this study was to elucidate the impact of performance status (PS) on the associations between VDRA use and outcomes among hemodialysis patients. This is a prospective cohort study. Adults on hemodialysis in the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry were included. Exposure of interest was the use of VDRA. Outcomes were all‐cause mortality and hip fracture. Associations between VDRA use and mortality or hip fractures were examined by Cox and Poisson regression analyses, respectively. Among 208,512 subjects, 128,535 were on VDRA. Poor PS was associated with higher calcium (Ca), lower parathyroid hormone, and higher alkaline phosphatase levels. The association between higher Ca levels and VDRA use was stronger among those with poor PS (p interaction 0.007). Adjusted hazard ratio (HR) (95% confidence interval [CI]) for mortality and incidence rate ratio (IRR) for hip fracture was 1.02 (95% CI, 0.99–1.05) and 0.93 (0.86–1.00) among users of VDRA, respectively. The VDRA use was associated with lower mortality and incidence of hip fractures among subjects with good PS but not among subjects with poor PS (p interaction 0.03 and 0.05). Effect modification by PS was observed for cardiovascular (CV) mortality but not for non‐CV mortality. In conclusion, VDRA use was associated with better outcomes only among those with good PS. These results suggest that bone and mineral disorders among hemodialysis patients should be treated differently, depending on their performance status. © 2022 American Society for Bone and Mineral Research (ASBMR).</description><subject>ALKALINE PHOSPHATASE</subject><subject>Bone resorption</subject><subject>CALCIUM</subject><subject>Cardiovascular diseases</subject><subject>Cohort analysis</subject><subject>Fractures</subject><subject>Hemodialysis</subject><subject>Hip</subject><subject>HIP FRACTURE</subject><subject>Immobilization</subject><subject>MORTALITY</subject><subject>Osteoporosis</subject><subject>Parathyroid hormone</subject><subject>PERFORMANCE STATUS</subject><subject>Vitamin D</subject><subject>VITAMIN D RECEPTOR ACTIVATOR</subject><issn>0884-0431</issn><issn>1523-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kcFu1DAQhiMEEkvhwBtY4tIe0tpO4iTctruUdtWqVbtwjQZnwnqVxMF2qPKSPFMn3Z6QeprR6Jv5f80fRZ8FPxWcy7P9r86dpkqKN9FCZDKJU1WIt9GCF0Ua8zQR76MP3u855ypTahH9u0PXWNdBr5E9BAijZze2No1Bz8IO2dJ7qw0EY3t2juERsWc_TYDO9GzN7lHjEKxjSx3MX5g76Gu64AK0JkyMBhcOdBgdfmVLduesH3Bmka3sjjASHWvi-me1DQzQoycrJIq0T97Y2kA7eePZdocOhokdbx7W2xMS76FlawhA7W_jg5s-Ru8aaD1-eqlH0Y-Lb9vVZXx9-_1qtbyOdVIqEdeJlDl9RNVYZhwbrWpdlmWdZbJWZZZriWnZJBKEUnlaFo2WkBY5AmY1lJlIjqLjw93B2T8j-lB1xmtsW3JvR19JlWeKq1wkhH75D93b0ZHzmSJRLqUqiDo5UJo-5B021eBMB26qBK_mZKs52WpOltizA_toWpxeB6vN-c3988YTRYGn4A</recordid><startdate>202208</startdate><enddate>202208</enddate><creator>Murashima, Miho</creator><creator>Hamano, Takayuki</creator><creator>Nishiyama, Takeshi</creator><creator>Tsuruya, Kazuhiko</creator><creator>Ogata, Satoshi</creator><creator>Kanda, Eiichiro</creator><creator>Abe, Masanori</creator><creator>Masakane, Ikuto</creator><creator>Nitta, Kosaku</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TS</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2100-9106</orcidid><orcidid>https://orcid.org/0000-0002-2923-0438</orcidid></search><sort><creationdate>202208</creationdate><title>Performance Status Modifies the Association Between Vitamin D Receptor Activator and Mortality or Fracture: A Prospective Cohort Study on the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry</title><author>Murashima, Miho ; Hamano, Takayuki ; Nishiyama, Takeshi ; Tsuruya, Kazuhiko ; Ogata, Satoshi ; Kanda, Eiichiro ; Abe, Masanori ; Masakane, Ikuto ; Nitta, Kosaku</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3961-d32278846de950efc6dc999d552d6957c2e49f32a1667498fc2a487eae5da9513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>ALKALINE PHOSPHATASE</topic><topic>Bone resorption</topic><topic>CALCIUM</topic><topic>Cardiovascular diseases</topic><topic>Cohort analysis</topic><topic>Fractures</topic><topic>Hemodialysis</topic><topic>Hip</topic><topic>HIP FRACTURE</topic><topic>Immobilization</topic><topic>MORTALITY</topic><topic>Osteoporosis</topic><topic>Parathyroid hormone</topic><topic>PERFORMANCE STATUS</topic><topic>Vitamin D</topic><topic>VITAMIN D RECEPTOR ACTIVATOR</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murashima, Miho</creatorcontrib><creatorcontrib>Hamano, Takayuki</creatorcontrib><creatorcontrib>Nishiyama, Takeshi</creatorcontrib><creatorcontrib>Tsuruya, Kazuhiko</creatorcontrib><creatorcontrib>Ogata, Satoshi</creatorcontrib><creatorcontrib>Kanda, Eiichiro</creatorcontrib><creatorcontrib>Abe, Masanori</creatorcontrib><creatorcontrib>Masakane, Ikuto</creatorcontrib><creatorcontrib>Nitta, Kosaku</creatorcontrib><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Physical Education Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of bone and mineral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murashima, Miho</au><au>Hamano, Takayuki</au><au>Nishiyama, Takeshi</au><au>Tsuruya, Kazuhiko</au><au>Ogata, Satoshi</au><au>Kanda, Eiichiro</au><au>Abe, Masanori</au><au>Masakane, Ikuto</au><au>Nitta, Kosaku</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Performance Status Modifies the Association Between Vitamin D Receptor Activator and Mortality or Fracture: A Prospective Cohort Study on the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry</atitle><jtitle>Journal of bone and mineral research</jtitle><date>2022-08</date><risdate>2022</risdate><volume>37</volume><issue>8</issue><spage>1489</spage><epage>1499</epage><pages>1489-1499</pages><issn>0884-0431</issn><eissn>1523-4681</eissn><abstract>ABSTRACT Immobilization osteoporosis is characterized by excess bone resorption. Vitamin D receptor activators (VDRA) might have adverse effects in immobilized patients. The objective of this study was to elucidate the impact of performance status (PS) on the associations between VDRA use and outcomes among hemodialysis patients. This is a prospective cohort study. Adults on hemodialysis in the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry were included. Exposure of interest was the use of VDRA. Outcomes were all‐cause mortality and hip fracture. Associations between VDRA use and mortality or hip fractures were examined by Cox and Poisson regression analyses, respectively. Among 208,512 subjects, 128,535 were on VDRA. Poor PS was associated with higher calcium (Ca), lower parathyroid hormone, and higher alkaline phosphatase levels. The association between higher Ca levels and VDRA use was stronger among those with poor PS (p interaction 0.007). Adjusted hazard ratio (HR) (95% confidence interval [CI]) for mortality and incidence rate ratio (IRR) for hip fracture was 1.02 (95% CI, 0.99–1.05) and 0.93 (0.86–1.00) among users of VDRA, respectively. The VDRA use was associated with lower mortality and incidence of hip fractures among subjects with good PS but not among subjects with poor PS (p interaction 0.03 and 0.05). Effect modification by PS was observed for cardiovascular (CV) mortality but not for non‐CV mortality. In conclusion, VDRA use was associated with better outcomes only among those with good PS. These results suggest that bone and mineral disorders among hemodialysis patients should be treated differently, depending on their performance status. © 2022 American Society for Bone and Mineral Research (ASBMR).</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><doi>10.1002/jbmr.4621</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2100-9106</orcidid><orcidid>https://orcid.org/0000-0002-2923-0438</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0884-0431
ispartof Journal of bone and mineral research, 2022-08, Vol.37 (8), p.1489-1499
issn 0884-0431
1523-4681
language eng
recordid cdi_proquest_miscellaneous_2675606713
source Wiley Online Library - AutoHoldings Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current)
subjects ALKALINE PHOSPHATASE
Bone resorption
CALCIUM
Cardiovascular diseases
Cohort analysis
Fractures
Hemodialysis
Hip
HIP FRACTURE
Immobilization
MORTALITY
Osteoporosis
Parathyroid hormone
PERFORMANCE STATUS
Vitamin D
VITAMIN D RECEPTOR ACTIVATOR
title Performance Status Modifies the Association Between Vitamin D Receptor Activator and Mortality or Fracture: A Prospective Cohort Study on the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T02%3A29%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Performance%20Status%20Modifies%20the%20Association%20Between%20Vitamin%20D%20Receptor%20Activator%20and%20Mortality%20or%20Fracture:%20A%20Prospective%20Cohort%20Study%20on%20the%20Japanese%20Society%20for%20Dialysis%20Therapy%20(JSDT)%20Renal%20Data%20Registry&rft.jtitle=Journal%20of%20bone%20and%20mineral%20research&rft.au=Murashima,%20Miho&rft.date=2022-08&rft.volume=37&rft.issue=8&rft.spage=1489&rft.epage=1499&rft.pages=1489-1499&rft.issn=0884-0431&rft.eissn=1523-4681&rft_id=info:doi/10.1002/jbmr.4621&rft_dat=%3Cproquest_cross%3E2699902268%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2699902268&rft_id=info:pmid/&rfr_iscdi=true